The Filing Desk

Regenxbio

RGNX · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

RGNX · Last close · November 13, 2026
$7.64
Value Regenxbio yourself

Regenxbio's revenue rose 104.5% to $170 million in fiscal 2025. Its operating margin was −94.6%, up from −280.0% a year earlier. Free cash flow was −$126 million. The diluted share count rose 4.2%.

REGENXBIO Inc. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001193125-26-094013 Updated
Revenue
$170M
104.5%
Operating margin
−94.6%
185.4 pts
Net income
−$194M
 
Free cash flow
−$126M
 
Return on equity
−107.0%
27.5 pts
Market cap
$499M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Gross margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Regenxbio does

Regenxbio develops gene therapies: one-time treatments that deliver a working gene into a patient's cells using harmless, modified viruses called AAV vectors. All of its therapies are built on its NAV Technology Platform, which it has held exclusive rights to since 2009. It focuses on retinal, neuromuscular and neurodegenerative diseases and makes its own therapies in U.S. facilities.

It has no product of its own on the market. It is developing a treatment for wet age-related macular degeneration and diabetic retinopathy with AbbVie, a treatment for Duchenne muscular dystrophy called RGX-202, and treatments for two inherited disorders, MPS II and MPS I, with Nippon Shinyaku. The FDA has issued a Complete Response Letter for the MPS II application, and has put clinical holds on both MPS programs.

For many years it also earned money by licensing its vectors to other drug makers. Licensees use them in programs such as Novartis's gene therapies for spinal muscular atrophy. At the end of February 2026 it had 371 full-time employees, most of them in research and development.

Its biggest risks, as it describes them

  • Clinical holds and a Complete Response Letter from the FDA may delay or end its MPS programs.
  • It expects to keep losing money, has never sold a product, and its cash may not cover the next 12 months.
  • Gene therapies are new, complex and hard to make, and it relies on third parties for some materials and testing.
  • Its trials may fail to show safety or effectiveness, or may cause serious side effects.
  • Its success depends partly on its licensing and collaboration partners such as AbbVie.
From Regenxbio's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2018 to 2021, earnings per share grew 2.2% a year and net income 8.6% a year, as new shares raised the share count by 20% and diluted each share's earnings. Regenxbio then lost money in fiscal 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments849565314245241
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage6.1x−11.3x−39.1x−18.4x−3.6x
Current ratio4.0x3.2x2.6x2.7x2.4x
Quick ratio4.0x3.2x2.6x2.7x2.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Regenxbio's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Regenxbio reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−273.0%−218.3%30.4%
Altman Z''−3.56−6.10−7.82
Accruals ratio−6.4%−10.4%−15.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rosePassPass—
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Regenxbio side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
RegenxbioFY25104.5%−94.6%−74.2%———
Beam TherapeuticsFY25120.0%−274.6%−257.6%———Compare
XencorFY2513.7%−141.3%−110.1%−19.9%—3Compare
Monte Rosa TherapeuticsFY2563.5%−43.8%−22.2%———Compare
Arcus BiosciencesFY25−4.3%−156.3%−195.9%——0Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue510218351554701139083170
Revenue growth−39.5%126.5%2,002.4%−83.9%338.7%204.3%−76.0%−19.9%−7.7%104.5%
Gross profit4920927119418585350—
Research and development465784124166181242232208228
Operating income−65−7688−149−119160−263−268−233−161
Net income−63−73100−95−111128−280−264−227−194
Diluted EPS (US$)−2.38−2.452.73−2.58−2.982.91−6.50−6.02−4.59−3.76
Diluted shares (millions)26303737374443445052
Cash flow
Cash from operations−49−58105−108−54219−208−218−173−124
Capital expenditure8713122784311022
Free cash flow−57−6591−119−81135−238−228−176−126
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation7111727323941403835
Balance sheet at fiscal year end
Cash and short-term investments159176471400522849565314245241
Debt incl. finance leases——————————
Total assets1731995444987081,114833574466453
Total liabilities11163548330350317262206350
Shareholders' equity162183509450378764516312260103
Margins and ratios
Gross margin97.9%83.6%95.6%76.6%76.9%89.0%51.6%58.8%59.7%—
Operating margin−1,423.8%−730.1%40.3%−422.9%−77.1%34.0%−233.2%−297.1%−280.0%−94.6%
Net margin−1,372.1%−704.0%45.7%−268.9%−72.0%27.2%−248.7%−292.0%−272.5%−113.8%
Free cash flow margin−1,235.7%−626.9%41.8%−339.0%−52.4%28.6%−211.3%−253.1%−210.7%−74.2%
Rule of 40 (growth + FCF margin)−1,275.2%−500.4%2,044.2%−422.8%286.3%232.9%−287.4%−273.0%−218.3%30.4%
Return on capital——————————
Return on equity−33.3%−42.5%28.9%−19.8%−26.9%22.4%−43.8%−63.6%−79.5%−107.0%
Return on assets−31.9%−39.4%26.9%−18.2%−18.4%14.0%−28.8%−37.5%−43.7%−42.2%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Regenxbio's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Regenxbio.